LENOIR, N.C. — Greer Labs announced the launch and commmercial availability of Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablets. The drug is used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.
“We are pleased to now be able to supply Oralair, which provides an additional option for treating grass allergies in the United States and helps to fill a current unmet need in allergy patient care,” said John G. Roby, Greer president and CEO. “Grass allergies affect millions of people, however we know that many patients who are candidates for immunotherapy refuse or discontinue allergy injections. Greer’s commitment to allergy innovation is guided by our desire to provide support to allergy specialists and relief to patients through immunotherapy.”
Greer Labs received FDA approval for the drug in April 2014. Oralair reduces grass allergy symptoms for patients within the first allergy season that it is administered, the company said. It is not indicated for the immediate relief of allergy symptoms.